Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
35.93
+1.13 (3.25%)
At close: Sep 8, 2025, 4:00 PM
36.95
+1.02 (2.84%)
Pre-market: Sep 9, 2025, 4:06 AM EDT

Mineralys Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-190.77-177.81-71.9-29.8-19.41-3.43
Depreciation & Amortization
0.060.04----
Loss (Gain) From Sale of Investments
-7.32-9.41-6.87-0.65--
Stock-Based Compensation
14.4711.345.060.460.080
Other Operating Activities
----0.680.48
Change in Accounts Payable
-6.184.162.423.014.470.54
Change in Other Net Operating Assets
-2.935.36-9.89-2.24-0.39-0.06
Operating Cash Flow
-192.69-166.31-81.17-29.22-14.56-2.46
Capital Expenditures
-0.04-0.1----
Investment in Securities
27.46115.06-160.47-21.76--
Investing Cash Flow
27.42114.96-160.47-21.76--
Short-Term Debt Issued
-----3.85
Total Debt Issued
-----3.85
Net Debt Issued (Repaid)
-----3.85
Issuance of Common Stock
199.34116.58203.25---
Other Financing Activities
-0.15-0.44--1.63--0.02
Financing Cash Flow
199.2116.14203.25128.0223.813.83
Net Cash Flow
33.9364.79-38.477.049.251.37
Free Cash Flow
-192.72-166.41-81.17-29.22-14.56-2.46
Free Cash Flow Per Share
-3.53-3.43-2.24-5.66-2.92-0.53
Levered Free Cash Flow
-122.12-99.43-55.27-18.4-7.62-
Unlevered Free Cash Flow
-122.12-99.43-55.27-18.4-7.61-
Change in Working Capital
-9.129.52-7.470.774.090.48
Updated Aug 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q